Key facts
- This page summarizes William L. Ashton's Form 4 filing for SPECTRUM PHARMACEUTICALS INC.
- 2 reported transactions and 1 derivative row are listed below.
- Accepted by SEC: 01 Aug 2023, 17:13.
William L. Ashton - 31 Jul 2023 Form 4 Insider Report for SPECTRUM PHARMACEUTICALS INC
- Reporting relationship
- Director
- Issuer ticker
- N/A
- Reported as of
- 31 Jul 2023
- Net transaction value
- $0
- SEC form
- 4
- Accepted by SEC
- 01 Aug 2023, 17:13:40 UTC
- Prior SEC filing
- 19 May 2023
- Next SEC filing
- 28 Aug 2023
- Source filing
- View source filing
- Reporting owner signature
- By: Keith M. McGahan For: William L. Ashton
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
William L. Ashton filed Form 4 for SPECTRUM PHARMACEUTICALS INC on 01 Aug 2023.
Change
- Previous filing in this sequence was filed on 19 May 2023.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
SPPI
transaction
Common Stock, $0.001 par value
Disposed to Issuer
- Transaction value
- Shares
- -67,660
- Change %
- -100%
- Price
- Shares after
- 0
- Date
- 31 Jul 2023
- Ownership
- Direct
- Footnotes
- F1
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
SPPI
transaction
Derivative
Stock Option (Right to Buy)
Disposed to Issuer
- Transaction value
- Shares
- -75,000
- Change %
- -100%
- Price
- Shares after
- 0
- Date
- 31 Jul 2023
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 75,000
- Exercise price
- $1.13
- Footnotes
- F2, F3
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Section 16 status
William L. Ashton is no longer subject to Section 16 filing requirements. Form 4 or Form 5 obligations may still apply in specific circumstances.
Explanation of responses 3 footnotes
Footnote F1
Represents shares of the Issuer disposed of pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated as of April 24, 2023, by and among the Issuer, Assertio Holdings, Inc., a Delaware corporation ("Acquiror"), and Spade Merger Sub 1, Inc., a Delaware corporation and a wholly owned subsidiary of Acquiror, in exchange for consideration of (a) 0.1783 of a share of the common stock of Acquiror and cash in lieu of fractional shares (the "Upfront Consideration") and (b) a contingent value right ("CVR") to receive up to an additional $0.20 per common share (subject to adjustment), payable in cash or common stock of Acquiror at the election of Acquiror, upon the achievement of certain milestones, (the Upfront Consideration plus one CVR, collectively, the "Merger Consideration") on the effective date of the merger.
Footnote F2
Stock options of the Issuer (the "Company Options") were canceled in the merger and (i) if the Company Option had an exercise price less than the Upfront Consideration, it was exchanged for (1) common stock of the Acquiror with a value equal to the quotient of (A) the product of (x) the total number of common stock of Issuer underlying the Company Option multiplied by (y) the excess, if any, of the value of the Upfront Consideration over the exercise price of such Company Option, divided by (B) the average of the daily volume-weighted average price per share of the common stock of Acquiror calculated based on the ten (10) consecutive trading days ending two trading days prior to the date of the Merger Agreement and (2) a number of CVRs equal to the number of shares of common stock of the Issuer underlying such Company Option, (ii) if the Company Option had an exercise price equal to or greater than the Upfront Consideration and less than the Merger Consideration,
Footnote F3
(Continued from Footnote 2) it was exchanged for a number of CVRs equal to the number of common stock of the Issuer underlying such Company Option (reduced by the amount that the exercise price exceeds the Upfront Consideration) and (iii) if the Company Option had an exercise price equal to or greater than the Merger Consideration, it was canceled for no consideration.